Analyzes of Hemorrhagic Obstetric Patients Whose Were Used Fibrinogen

Treatment of Obstetric Hemorrhage With Fibrinogen and Blood Products: Retrospective Analyzes

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03723200

Enrollment

Registered

2018-10-29

Start date

2018-10-09

Completion date

2018-10-24

Last updated

2018-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhage

Keywords

Hemorrhagic, Obstetric, Fibrinogen

Brief summary

The files of hemorrhagic obstetric patients undergoing surgery and followed in the intensive care unit and using Fibrinogen and blood products were included in the study between January 2015- September 2018 at the Anesthesiology and Reanimation Clinic of SBU Kanuni Sultan Süleyman Training and Research Hospital. Patients under 18 years of age were excluded from the study. In this study, ages, operation types, number of blood and products, the amount of fibrinogen, the results of the hemogram and bleeding parameters, the levels of fibrinogen, the duration of hospital stay and the intensive care unit were recorded.

Detailed description

Bleeding is an important event that threatens the patient's life. Too much blood and blood products can be used in massive bleeding. However, unwanted allergic reactions may occur in blood and blood product transfusions. Fibrinogen is the first coagulation factor in coagulopathy. Some studies have shown that when the fibrinogen level falls to \<150-200 mg / dl, the bleeding increases dramatically.

Interventions

OTHERFibrinogen and blood products

Fibrinogen and blood products

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Inclusion criteria

* Obstetric patients, underwent surgery and followed in ICU * Used Fibrinogen and Blood products * Over 18 years age

Exclusion criteria

* Under 18 years age * Obstetric patients, underwent surgery but not used Fibrinogen and Blood products

Design outcomes

Primary

Measure	Time frame	Description
Amount of blood products (unit)	24 hours	degree of hemorrhagie
Measurement of hemoglobin (g/dL)	24 hours	Postpartum hemorrhage (PPH) is a major contributor to maternal death and severe maternal morbidity
Amount of fibrinogen consantrates	24 hours	in order to avoid PPH
Measurement of fibrinogen (mg/L)	24 hours	Significant independent predictor for evolution to severe PPH was plasma fibrinogen level.

Secondary

Measure	Time frame	Description
Hospital stay days	24 hours	for the recovery time of patients

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026